Proteomics Intl Labs Ltd has released a press release.
Clinical Utility Study demonstrates PromarkerD test benefits
Filed with ASX ·
6ix hasn’t read this filing yet.
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Potential breakthrough blood test for endometriosis
- June 2022 Quarterly Activities Report and Appendix 4C
- European PromarkerD patents expanded beyond diabetes
- Endometriosis clinical validation study readout positive
- Proteomics secures licence to oesophageal cancer biomarkers
Later from Proteomics International Laboratories
- Proteomics signs binding LOI with Sonic Healthcare USA
- Proteomics raises $8m in highly successful Placement
- Completion of Placement and Exercise of Performance Rights
- OxiDx launched to maximise oxidative stress technology
- New Oesophageal Cancer Diagnostic shows strong performance
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories